Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody Drug Conjugate, in Adults with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: a Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase 2a Trial.
Frank ButtgereitJacob AelionBernadette RojkovichAnna Zubrzycka-SienkiewiczSu ChenYang YangDilek ArikanRonilda D'CunhaYinuo PangHartmut KupperTimothy RadstakeHoward AmitalPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
Data from this proof-of-concept trial support the continued development of a TNF-GRM-ADC for the treatment of RA, with the potential to achieve superior outcomes compared to currently available therapies.
Keyphrases
- human health
- rheumatoid arthritis
- risk assessment
- phase iii
- study protocol
- phase ii
- clinical trial
- disease activity
- double blind
- interstitial lung disease
- placebo controlled
- ankylosing spondylitis
- open label
- electronic health record
- high dose
- high intensity
- early onset
- cancer therapy
- randomized controlled trial
- type diabetes
- magnetic resonance imaging
- drug delivery
- metabolic syndrome
- replacement therapy
- data analysis
- binding protein
- low dose
- mesenchymal stem cells
- systemic sclerosis
- machine learning
- weight loss